Trial Profile
Capecitabine plus irinotecan with or without apatinib for advanced colorectal cancer: an open label, controlled, prospective phase II trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Capecitabine; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 02 Nov 2018 New trial record